Market capitalization | $279.58m |
Enterprise Value | $127.08m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 24.30 |
P/S ratio (TTM) P/S ratio | 53.46 |
P/B ratio (TTM) P/B ratio | 1.57 |
Revenue growth (TTM) Revenue growth | 884.75% |
Revenue (TTM) Revenue | $5.23m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:
6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 5.23 5.23 |
887%
887%
|
|
Gross Profit | 4.34 4.34 |
43,300%
43,300%
|
|
EBITDA | -211 -211 |
36%
36%
|
EBIT (Operating Income) EBIT | -211 -211 |
36%
36%
|
Net Profit | -215 -215 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Head office | United States |
CEO | Michael Exton |
Employees | 285 |
Founded | 1995 |
Website | www.lexpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.